UniQure Faces Class Action Lawsuit
Analysis based on 222 articles · First reported Feb 11, 2026 · Last updated Apr 12, 2026
The class action lawsuit against UniQure is expected to negatively impact its stock price and investor confidence due to allegations of misleading statements. This event underscores the importance of regulatory compliance and transparent communication for publicly traded companies, potentially increasing scrutiny on similar firms in the biotechnology sector.
The Schall Law Firm has initiated a class action lawsuit against UniQure N.V. for alleged violations of the Securities Exchange Act of 1934. The lawsuit claims that UniQure made false and misleading statements to investors between September 24, 2025, and October 31, 2025, regarding the FDA approval of its Pivotal Study and the potential delays in its Biologics License Application (BLA) timeline. Investors who purchased UniQure's securities during this period and suffered losses are encouraged to join the lawsuit before April 13, 2026. The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally. The allegations suggest that UniQure failed to secure full FDA approval and misled the market about the need to supplement data, leading to investor damages when the truth emerged.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard